Second-line treatments of small-cell lung cancers.

about

Second-line treatments of small-cell lung cancers.

Item

http://www.wikidata.org/entity/Q47789861

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Second-line treatments of small-cell lung cancers.

@en

Second-line treatments of small-cell lung cancers.

@nl

type

Item

label

Second-line treatments of small-cell lung cancers.

@en

Second-line treatments of small-cell lung cancers.

@nl

prefLabel

Second-line treatments of small-cell lung cancers.

@en

Second-line treatments of small-cell lung cancers.

@nl

P1476

Second-line treatments of small-cell lung cancers.

@en

P2093

Gilles Quere

http://www.w3.org/2001/XMLSchema#string

Henri Janicot

http://www.w3.org/2001/XMLSchema#string

Isabelle Monnet

http://www.w3.org/2001/XMLSchema#string

Jean Bernard Auliac

http://www.w3.org/2001/XMLSchema#string

Laurent Greillier

http://www.w3.org/2001/XMLSchema#string

Mallorie Kerjouan

http://www.w3.org/2001/XMLSchema#string

Nathalie Baize

http://www.w3.org/2001/XMLSchema#string

P2860

A small-cell lung cancer genome with complex signatures of tobacco exposure

Notch signaling in human development and disease

Phase II study of paclitaxel, ifosfamide, and cisplatin as second-line treatment in relapsed small-cell lung cancer.

Etoposide plus cisplatin with or without the combination of 4'-epidoxorubicin plus cyclophosphamide in treatment of extensive small-cell lung cancer: a French Federation of Cancer Institutes multicenter phase III randomized study.

Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin, and etoposide: a non-cross-resistant schedule.

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer.

Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer.

Paclitaxel in combination with carboplatin as salvage treatment in refractory small-cell lung cancer (SCLC): a multicenter phase II study.

Single-agent gemcitabine in patients with resistant small-cell lung cancer.

Phase II study of weekly irinotecan and carboplatin for refractory or relapsed small-cell lung cancer.

P304

1033-1043

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/14737140.2017.1372198

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christos Chouaid

Alain Vergnenegre

P577

2017-08-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28849951

http://www.w3.org/2001/XMLSchema#string